The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Immune fitness and teclistamab response: MajesTEC-1 subanalysis
|
A subanalysis on the impact of immune fitness on response to teclistamab from MajesTEC-1 has been published in Blood by Cortes-Selva et al.1 Researchers compared tumor characteristics and immune profiles of the 165 patients with relapsed/refractory multiple myeloma (RRMM) with response to 1.5 mg/kg teclistamab. |
|
Key learnings: |
|
There was a relationship identified between immune profiles and response to teclistamab. |
|
Most notably, a higher baseline T-cell count in the peripheral blood was associated with improved response. |
|
Patients who did not respond to teclistamab generally possessed immune profiles suggestive of immune suppression and T-cell dysfunction, with higher frequencies of T cells expressing exhaustion markers. |
|
Increased progression-free survival rates were linked to lower frequencies of T cells with exhaustion markers at baseline. |
|
These findings suggest that assessing baseline immune profiles could help predict response to teclistamab and aid in the development of personalized treatment plans. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
